Evolving Ablative Therapies for Hepatic Malignancy

por Singla, Smit, Hochwald, Steven N., Kuvshinoff, Boris
Publicado 2014

Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study

por Samuel, Sandeep, Mukherjee, Sarbajit, Ammannagari, Nischala, Pokuri, Venkata K., Kuvshinoff, Boris, Groman, Adrienne, LeVea, Charles M., Iyer, Renuka
Publicado 2018

CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma

por Agrawal, Shefali, Kuvshinoff, Boris W., Khoury, Thaer, Yu, Jihnhee, Javle, Milind M., LeVea, Charles, Groth, Jeff, Coignet, Lionel J., Gibbs, John F.
Publicado 2007

Immune profiling and immunotherapeutic targets in pancreatic cancer

por Lenzo, Felicia L., Kato, Shumei, Pabla, Sarabjot, DePietro, Paul, Nesline, Mary K., Conroy, Jeffrey M., Burgher, Blake, Glenn, Sean T., Kuvshinoff, Boris, Kurzrock, Razelle, Morrison, Carl
Publicado 2021

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

por Dy, Grace K., Nesline, Mary K., Papanicolau-Sengos, Antonios, DePietro, Paul, LeVea, Charles M., Early, Amy, Chen, Hongbin, Grand’Maison, Anne, Boland, Patrick, Ernstoff, Marc S., Edge, Stephen, Akers, Stacey, Opyrchal, Mateusz, Chatta, Gurkamal, Odunsi, Kunle, Pabla, Sarabjot, Conroy, Jeffrey M., Glenn, Sean T., DeFedericis, Hanchun T., Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Maochun, Wang, Yirong, Kanehira, Kazunori, Lenzo, Felicia L., Frederick, Peter, Lele, Shashikant, Galluzzi, Lorenzo, Kuvshinoff, Boris, Morrison, Carl
Publicado 2019